Capmatinib Could Alter NSCLC Treatment Landscape Available to Purchase

Capmatinib may be effective in patients with advanced non–small cell lung cancer who have MET exon 14 skipping mutations. In the phase II GEOMETRY mono-1 trial, the drug elicited high overall response rates and relatively durable responses in newly diagnosed and previously treated patients, including those with brain metastases.